FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dick Pluim

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Dick Pluim; Jos H Beijnen; Lot A Devriese; Jan H M Schellens
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Dick Pluim; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dick Pluim (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Investigational new drugs 2013;31(3):800.
2012: Dick Pluim; Jos H Beijnen; Lot A Devriese; Jan H M Schellens
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2012;81(8):664-71.
2009: Dick Pluim; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3549-55.
2009: David Boss; Wandena S Siegel-Lakhai; Nadja E van Egmond-Schoemaker; Dick Pluim; Hilde Rosing; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4475-83.
2008: Stephan A Veltkamp; Dick Pluim; Monique van Eijndhoven; Maria J Bolijn; Felix H G Ong; Rajgopal Govindarajan; Jashvant D Unadkat; Jos H Beijnen; Jan H M Schellens
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Molecular cancer therapeutics 2008;7(8):2415-25.
2008: Stephan A Veltkamp; Dick Pluim; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1606-15.
2008: Stephan A Veltkamp; Robert Jansen; Sophie Callies; Dick Pluim; Carla M Visseren-Grul; Hilde Rosing; Susanne Kloeker-Rhoades; Valerie A M Andre; Jos H Beijnen; Christopher A Slapak; Jan H M Schellens
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3477-86.
2008: E E M Brouwers; Matthijs M Tibben; Dick Pluim; Hilde Rosing; H Boot; A Cats; J H M Schellens; Jos H Beijnen
Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.
Analytical and bioanalytical chemistry 2008;391(2):577-85.
2008: Frank J P Hoebers; Dick Pluim; Augustinus A M Hart; Marcel Verheij; Alfons J M Balm; G Fons; Coen R N Rasch; J H M Schellens; L J A Stalpers; Harry Bartelink; Adrian C Begg
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer chemotherapy and pharmacology 2008;61(6):1075-81.
2007: Serena Marchetti; Roos L Oostendorp; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Alfred H Schinkel; Richard Versace; Jos H Beijnen; Roberto Mazzanti; Jan H Schellens
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Molecular cancer therapeutics 2007;6(12 Pt 1):3307-13.
2007: Pauline Breedveld; Dick Pluim; Greta Cipriani; Femke Dahlhaus; Monique van Eijndhoven; Cornelia J F De Wolf; Annemieke Kuil; Jos H Beijnen; George L Scheffer; Gerrit Jansen; Piet Borst; Jan H M Schellens
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Molecular pharmacology 2007;71(1):240-9.
2006: Frank J P Hoebers; Dick Pluim; Marcel Verheij; Alfons J M Balm; Harry Bartelink; Jan H M Schellens; Adrian C Begg
Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
International journal of cancer. Journal international du cancer 2006;119(4):750-6.
2005: Wandena S Siegel-Lakhai; Mirjam Crul; Steven Zhang; Rolf W Sparidans; Dick Pluim; A Howes; B Solanki; Jos H Beijnen; J H M Schellens
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Jeany M Rademaker-Lakhai; Mirjam Crul; Dick Pluim; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Anti-cancer drugs 2005;16(9):1029-36.
2005: Jan-Hendrik Beumer; Michel J X Hillebrand; Dick Pluim; Hilde Rosing; Karen Foley; S Murray Yule; Jan H M Schellens; Jos H Beijnen
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.
Investigational new drugs 2005;23(4):317-30.
2005: Pauline Breedveld; Dick Pluim; Greta Cipriani; peter wielinga; Olaf van Tellingen; Alfred H Schinkel; Jan H M Schellens
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Cancer research 2005;65(7):2577-82.
2004: Robert C A M van Waardenburg; Laurina A de Jong; Monique van Eijndhoven; Caroline Verseyden; Dick Pluim; Lars E T Jansen; Mary-Ann Bjornsti; Jan H M Schellens
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
The Journal of biological chemistry 2004;279(52):54502-9.
2004: Pauline Breedveld; Noam Zelcer; Dick Pluim; Ozgür Sönmezer; Matthijs M Tibben; Jos H Beijnen; Alfred H Schinkel; Olaf van Tellingen; Piet Borst; Jan H M Schellens
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Cancer research 2004;64(16):5804-11.
2004: Dick Pluim; Robert C A M van Waardenburg; Jos H Beijnen; Jan H M Schellens
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Cancer chemotherapy and pharmacology 2004;54(1):71-8.
2004: Jeany M Rademaker-Lakhai; Desiree van den Bongard; Dick Pluim; Jos H Beijnen; Jan H M Schellens
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3717-27.
2004: Jeany M Rademaker-Lakhai; Catherine Terret; Stephen B Howell; Christiane M Baud; Richard F De Boer; Dick Pluim; Jos H Beijnen; Jan H M Schellens; Jean Pierre Droz
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3386-95.
2003: Mirjam Crul; Nadja E Schoemaker; Dick Pluim; Marc Maliepaard; René W M Underberg; Margaret Schot; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3526-33.
2003: H J G D van den Bongard; Dick Pluim; R C A M van Waardenburg; Miroslav Ravic; Jos H Beijnen; J H M Schellens
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Anti-cancer drugs 2003;14(6):405-10.
2003: Mirjam Crul; Robert C A M van Waardenburg; Suzanne Bocxe; Monique van Eijndhoven; Dick Pluim; Jos H Beijnen; Jan H M Schellens
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Biochemical pharmacology 2003;65(2):275-82.
2002: H J G Desirée van sen Bongard; Dick Pluim; Hilde Rosing; Lianda G A H Nan-Offeringa; Margaret Schot; Miroslav Ravic; Jan H M Schellens; Jos H Beijnen
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
Anti-cancer drugs 2002;13(8):807-14.
2002: Jetske M Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M Tibben; Albert Huisman; Wim W ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E Voest; Jos H Beijnen; Jan M Schellens
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2002: Nadja E Schoemaker; Virginie M M Herben; Laurina A de Jong; Robert C A M van Waardenburg; Dick Pluim; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Anti-cancer drugs 2002;13(1):87-91.
2001: Marc Maliepaard; Margôt van Gastelen; A Tohgo; FREDERICK HAUSHEER; Robert C A M van Waardenburg; Laurina A de Jong; Dick Pluim; Jos H Beijnen; J H M Schellens
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
1999: Dick Pluim; Marc Maliepaard; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: Marc Maliepaard; Margôt van Gastelen; Laurina A de Jong; Dick Pluim; Robert C A M van Waardenburg; M C Ruevekamp-Helmers; BG Floot; J H M Schellens
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer research 1999;59(18):4559-63.
1999: M de Graaff; Marc Maliepaard; Dick Pluim; B J Floot; Ineke Slaper-Cortenbach; J H M Schellens
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Anti-cancer drugs 1999;10(2):213-8.